Research Topics
| Jean Michel MolinaSummaryCountry: France Publications
| Collaborators
|
Detail Information
Publications
Once-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJean Michel Molina
Department of Infectious Diseases, Hopital Saint Louis 1, Av C Vellefaux, 75475 Paris, Cedex 10, France
J Acquir Immune Defic Syndr 53:323-32. 2010..Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48 weeks, with less gastrointestinal disturbance and a better lipid profile, in treatment-naive patients...
Didanosine in HIV-1-infected patients experiencing failure of antiretroviral therapy: a randomized placebo-controlled trialJean Michel Molina
Department of Infectious Diseases, Saint Louis Hospital, Paris, France
J Infect Dis 191:840-7. 2005..The antiviral efficacy of didanosine in patients experiencing virological failure is not well known...
Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trialJean Michel Molina
Assistance Publique Hopitaux de Paris, Paris, France
J Infect Dis 191:830-9. 2005..We assessed a once-daily combination to simplify therapy in patients infected with human immunodeficiency virus type 1 (HIV-1)...
Fumagillin treatment of intestinal microsporidiosisJean Michel Molina
Department of Infectious Diseases, Hôpital Saint Louis and University of Paris VII, Paris, France
N Engl J Med 346:1963-9. 2002..Intestinal microsporidiosis due to Enterocytozoon bieneusi is a cause of chronic diarrhea, malabsorption, and wasting in immunocompromised patients. Currently, there is no effective treatment...
Five-year follow up of once-daily therapy with emtricitabine, didanosine and efavirenz (Montana ANRS 091 trial)Jean Michel Molina
Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris 7, France
Antivir Ther 12:417-22. 2007..Once-daily combination therapy with emtricitabine, didanosine and efavirenz has been highly effective in clinical trials but its long-term efficacy and safety has not been previously reported...
Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE studyJean Michel Molina
Department of Infectious Diseases, Saint Louis Hospital, AP HP, Paris University of Paris Diderot, Paris 7, France
Lancet 372:646-55. 2008..We compared these two combinations directly in treatment-naive patients...
Switch from enfuvirtide to raltegravir lowers plasma concentrations of darunavir and tipranavir: a pharmacokinetic substudy of the EASIER-ANRS 138 trialLauriane Goldwirt
Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, and University Paris 11, Le Kremlin Bicetre, France
Antimicrob Agents Chemother 55:3613-5. 2011..49, 0.76, and 0.67 and 0.82, 0.68, and 0.64 for tipranavir and darunavir, respectively. The virologic consequences of these drug interactions have yet to be determined...
Liver fibrosis changes in HIV-HBV-coinfected patients: clinical, biochemical and histological effect of long-term tenofovir disoproxil fumarate useAnders Boyd
INSERM UMR S707, Paris, France
Antivir Ther 15:963-74. 2010..The effect of TDF on liver fibrosis in 148 HIV-HBV-coinfected patients was prospectively evaluated using Fibrometer∆ scores and liver biopsies in a subset of patients...
Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapyJuliette Pavie
Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, University of Paris Diderot Paris 7, France
J Antimicrob Chemother 66:2372-8. 2011..Limited data are available on the use of unboosted atazanavir in combination with nucleoside reverse transcriptase inhibitors (NRTIs) in treatment-experienced HIV-infected patients...
Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosineAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, Paris, France
Antivir Ther 11:693-9. 2006..To determine the potential impact of reverse transcriptase (RT) mutations, other than those currently known to confer nucleoside reverse transcriptase inhibitors (NRTIs) resistance, on the virological response to didanosine (ddl)...
Salvage therapy with atazanavir/ritonavir combined to tenofovir in HIV-infected patients with multiple treatment failures: randomized ANRS 107 trialChristophe Piketty
Department of Immunology, Hôpital Georges Pompidou, Assistance Publique Hopitaux de Paris, Paris, France
Antivir Ther 11:213-21. 2006..Ritonavir (RTV)-boosted atazanavir (ATV) and tenofovir disoproxil fumarate (TDF-DF) are promising in highly experienced patients because of their pharmacokinetic profile, activity, safety and resistance properties...
Efficacy and safety of raltegravir in treatment-experienced HIV-1-infected patients switching from enfuvirtide-based regimens: 48 week results of the randomized EASIER ANRS 138 trialSebastien Gallien
Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital, Paris, France
J Antimicrob Chemother 66:2099-106. 2011..To assess the sustainable efficacy and safety of a switch from enfuvirtide to raltegravir in patients with multidrug-resistant HIV infection...
A lopinavir/ritonavir-based once-daily regimen results in better compliance and is non-inferior to a twice-daily regimen through 96 weeksJean Michel Molina
Hopital Saint Louis, AP HP, and University of Paris 7, Paris, France
AIDS Res Hum Retroviruses 23:1505-14. 2007..LPV/r QD resulted in virologic response similar to LPV/r BID through 96 weeks in antiretroviral-naive subjects. Adherence was significantly higher in the QD group...
Risk factors for acute liver enzyme abnormalities in HIV-hepatitis B virus-coinfected patients on antiretroviral therapyOlivia Chauvel
AP HP, Hopital Saint Antoine, Service de Maladies Infectieuses et Tropicales, Paris, France
Antivir Ther 12:1115-26. 2007..Little is known about the prognostic factors of acute liver enzyme variations in HIV-hepatitis B virus (HBV)-coinfected patients...
Pattern and impact of emerging resistance mutations in treatment experienced patients failing darunavir-containing regimenConstance Delaugerre
Virology Department, Saint Louis Hospital APHP, Paris, France
AIDS 22:1809-13. 2008..Limited data are available on resistance pattern emerging in patients failing DRV/r and on subsequent remaining protease inhibitor options...
Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase 3, non-inferiority studyJean Michel Molina
Hôpital Saint Louis and University of Paris Diderot, Paris, France
Lancet Infect Dis 12:27-35. 2012..We aimed to compare the efficacy and safety of elvitegravir with raltegravir, another HIV-1 integrase inhibitor, in patients in whom previous antiretroviral treatment failed...
Time course of total HIV-1 DNA and 2-long-terminal repeat circles in patients with controlled plasma viremia switching to a raltegravir-containing regimenConstance Delaugerre
Virology Department, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
AIDS 24:2391-5. 2010..In vitro, integrase inhibitors reduce proviral DNA levels and rapidly increase 2-long-terminal repeat (LTR) circle levels. We examined the effect of raltegravir on the time course of HIV-1 DNA forms in patients with controlled viremia...
Incidence and risk factors of thrombocytopenia in patients receiving intermittent antiretroviral therapy: a substudy of the ANRS 106-window trialMarie Anne Bouldouyre
Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hôpitaux de Paris and University of Paris Diderot Paris 7, France
J Acquir Immune Defic Syndr 52:531-7. 2009..Incidence and risk factors for thrombocytopenia in patients discontinuing highly active antiretroviral therapy (HAART) have not been fully investigated...
Low frequency of intermittent HIV-1 semen excretion in patients treated with darunavir-ritonavir at 600/100 milligrams twice a day plus two nucleoside reverse transcriptase inhibitors or monotherapySidonie Lambert-Niclot
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, Paris, France
Antimicrob Agents Chemother 54:4910-3. 2010..The median darunavir seminal plasma concentration was close to the blood plasma free fraction, demonstrating a good penetration of darunavir into the male genital tract...
High concentration of raltegravir in semen of HIV-infected men: results from a substudy of the EASIER-ANRS 138 trialCaroline Barau
Department of Clinical Pharmacy, Bicetre Hospital, Assistance Publique Hopitaux de Paris, 78 rue du General Leclerc, 94275 Le Kremlin Bicetre, France
Antimicrob Agents Chemother 54:937-9. 2010..The median semen-to-plasma ratio of raltegravir concentration was 1.42 (range, 0.52 to 6.66), indicating good although variable levels of drug penetration of raltegravir in the seminal compartment...
Impact of low-level-viremia on HIV-1 drug-resistance evolution among antiretroviral treated-patientsConstance Delaugerre
Laboratoire de Virologie, Hôpital Saint Louis APHP, Paris, France
PLoS ONE 7:e36673. 2012..Our objective was to determine the emergence and evolution of DRAM during LLV in HIV-1-infected patients while receiving antiretroviral therapy (ART)...
Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial)Sebastien Gallien
Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Department of Infectious Diseases, University of Paris Diderot Paris 7, Paris, France
J Antimicrob Chemother 66:184-91. 2011..once-daily combinations of efavirenz and two nucleoside analogues are recommended for the treatment of HIV infection. Long-term efficacy and safety data are scarce for the combination of efavirenz, emtricitabine and didanosine...
Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialJean Michel Molina
Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot, Paris, France
Lancet 378:238-46. 2011..We aimed to assess the efficacy, safety, and tolerability of rilpivirine versus efavirenz, each combined with tenofovir-disoproxil-fumarate and emtricitabine...
Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in treatment-experienced patients: 24-week results of POWER 3Jean Michel Molina
Assistance Publique Hopitaux de Paris, Department of Infectious Diseases, Hopital St Louis, Paris, France
J Acquir Immune Defic Syndr 46:24-31. 2007..To examine the efficacy and safety of the selected darunavir/r dose further, additional patients were analyzed...
Once-daily administration of antiretrovirals: pharmacokinetics of emerging therapiesAnne Marie Taburet
Clinical Pharmacy, Hospital Bicetre, Assistance Publique Hopitaux de Paris, France
Clin Pharmacokinet 42:1179-91. 2003..Preliminary results from these small pilot studies suggest that once-daily administration of antiretrovirals is a feasible approach. Large comparative trials are needed before the real benefits of such a strategy can be fully assessed...
Comparison of the antiviral activity of adefovir and tenofovir on hepatitis B virus in HIV-HBV-coinfected patientsKarine Lacombe
INSERM UMR S707, Paris, France
Antivir Ther 13:705-13. 2008..Characteristics and factors influencing viral decay under tenofovir (TDF) and adefovir (ADV) need to be determined in HIV-HBV-coinfected patients...
Development of a real-time polymerase-chain-reaction assay for quantitative detection of Enterocytozoon bieneusi DNA in stool specimens from immunocompromised patients with intestinal microsporidiosisJean Menotti
Laboratory of Parasitology-Mycology, , , , , Paris, France
J Infect Dis 187:1469-74. 2003..In conclusion, this real-time PCR assay is a reliable tool for quantitation of E. bieneusi DNA in stool specimens and for the monitoring of treatment efficacy...
Impact of chronic hepatitis C and/or D on liver fibrosis severity in patients co-infected with HIV and hepatitis B virusKarine Lacombe
INSERM, UMR S707, Paris, F 75012, France
AIDS 21:2546-9. 2007..02, 95% CI = 1.03-97.42 for HBV-HCV-HDV, compared to OR = 1.76, 95% CI = 0.50-6.17 for HBV alone]. Co-treatment of other multiple viral hepatitis infections should also be taken into consideration, especially in the case of chronic HDV...
Clinical and resistance consequences of misquantification of plasma and cerebrospinal fluid human immunodeficiency virus type 1 (HIV-1) RNA in samples from an HIV-1 subtype G-infected patientConstance Delaugerre
Department of Virology, Saint Louis Hospital, 1 avenue Claude Vellefaux, 75010 Paris, France
J Clin Microbiol 47:3763-4. 2009..We report a case of underquantification of HIV type 1 (HIV-1) RNA in plasma and cerebrospinal fluid from an HIV-1 subtype G-infected woman, leading to delayed diagnosis of HIV encephalitis and to the emergence of drug resistance...
Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nCathia Soulie
Université Pierre et Marie Curie Paris, UMR S 943, INSERM, U943, Paris, France
AIDS 23:1605-8. 2009..The NNRTI + protease inhibitor strategy should not be recommended as an antiretroviral first-line regimen, particularly in patients with high viral load at baseline...
Phenotypic susceptibility to didanosine is associated with antiviral activity in treatment-experienced patients with HIV-1 infectionPhilippe Flandre
Unité INSERM U720, BP 335 75625, Paris, France
J Infect Dis 195:392-8. 2007..We investigated the relationship between human immunodeficiency virus (HIV) phenotypic susceptibility to didanosine and the antiviral activity of didanosine (ddI) in the JAGUAR study...
Pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patientsAurélie Barrail-Tran
AP HP, Hospital Bicetre, Paris, France
AIDS 24:2581-3. 2010..118 and 3837 vs. 2241 ng/ml) and darunavir area under the curve (AUC(12h)) (50 083 vs. 36 277 ng h/ml). All pharmacokinetic parameters appeared to be highly variable regardless to the addition of etravirine...
Prevalence of antibodies and RNA genome of hepatitis E virus in a cohort of French immunocompromisedSarah Maylin
Virology Dpt, INSERM U941 Paris 7 Diderot University, Saint Louis Hospital APHP, Paris, France
J Clin Virol 53:346-9. 2012..Recently, cases of chronic hepatitis E have been identified in immunocompromised patients...
Varicella-zoster virus-specific cell-mediated immune responses in HIV-infected adultsNathalie de Castro
Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, University of Paris Denis Diderot, France
AIDS Res Hum Retroviruses 27:1089-97. 2011..HIV-infected patients with a history of AIDS or low CD4 cell counts have impaired VZV-specific CMI responses, and remain at risk for herpes zoster...
Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adultsClaire Rabian
Laboratoire d Immunologie et d Histocompatibilité, St Louis Hospital, Paris, France
Clin Infect Dis 50:1174-83. 2010..CD4 T cell responses specific to the diphtheria-derived carrier protein CRM(197) were evaluated...
Case report: Cure of chronic infection with hepatitis C virus after 6 weeks of peg-interferon and ribavirin in a patient co-infected with HIVAnne Rachline
Department of Infectious Diseases, Hopital Saint Louis, Paris, France
J Med Virol 82:1150-1. 2010..This report describes a patient co-infected with HCV genotype 2 and HIV who discontinued HCV therapy after 6 weeks because of adverse events and had a sustained virologic response...
Prevalence of opportunistic intestinal parasitic infections among HIV-infected patients with low CD4 cells counts in France in the combination antiretroviral therapy eraJuliette Pavie
Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot Paris 7, 1 avenue Claude Vellefaux, 75010 Paris, France
Int J Infect Dis 16:e677-9. 2012....
Pharmacogenetics of toxicity, plasma trough concentration and treatment outcome with nevirapine-containing regimen in anti-retroviral-naïve HIV-infected adults: an exploratory study of the TRIANON ANRS 081 trialClaire Gozalo
Department of Molecular Genetics, Pharmacogenetics and Hormonology, Assistance Publique Hopitaux de Paris, Bicetre Hospital, France
Basic Clin Pharmacol Toxicol 109:513-20. 2011....
Severe acute renal failure in an HIV-infected patient after only 2 weeks of tenofovir-based antiretroviral therapyJuliette Pavie
Department of Infectious Diseases, Saint Louis Hospital, University of Paris Diderot, France
AIDS Patient Care STDS 25:457-60. 2011..Although severe renal toxicity due to tenofovir is rare, patients receiving tenofovir must be monitored closely for renal dysfunction especially during the first weeks of tenofovir therapy...
Prevalence of intestinal parasites including microsporidia in human immunodeficiency virus-infected adults in Cameroon: a cross-sectional studyClaudine Sarfati
Laboratory of Parasitology and Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hopitaux de Paris, Paris, France
Am J Trop Med Hyg 74:162-4. 2006..parvum in six patients, and Isospora belli in three patients. All E. bieneusi isolates tested belonged to the same genotype. The prevalence of opportunistic protozoa among patients with CD4 cell counts less than 50/mm(3) was 32%...
Development of a real-time PCR assay for quantitative detection of Encephalitozoon intestinalis DNAJean Menotti
Laboratory of Parasitology Mycology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, and Faculté de Médecine Lariboisière Saint Louis, Universite Paris VII, Paris, France
J Clin Microbiol 41:1410-3. 2003..intestinalis DNA in blood and serum. We conclude that real-time PCR is a valuable tool for quantitation of E. intestinalis burden in clinical specimens...
Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trialMatthieu Lafaurie
Department of Infectious Diseases, Saint Louis Hospital, University of Paris 7, INSERM U897, 1 avenue Claude Vellefaux 75010 Paris, France
J Antimicrob Chemother 62:1122-9. 2008..However, it is unclear whether patients tolerating long-term zidovudine-containing regimens will benefit from a switch to non-zidovudine-containing regimens...
Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman diseaseSégolène Neuville
Department of Infectious Diseases, Saint Louis Hospital, University of Paris, AP HP, Paris, France
Am J Hematol 79:337-9. 2005..Clinical and virologic relapses with increased blood human herpesvirus-8 DNA levels occurred in both patients 4 and 24 weeks later and were associated with a worsening of Kaposi sarcoma...
Quality of travel health advice in a French travel medicine and vaccine center: a prospective observational studyMarie Anne Bouldouyre
Department of Infectious Diseases, Hospital Saint Louis, Paris, France
J Travel Med 19:76-83. 2012..The number of international trips undertaken by French citizens is rising and we wished to assess the appropriateness of advices given to travelers in a vaccine and travel medicine center in France...
Comparative RNA quantification of HIV-1 group M and non-M with the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 v2.0 and Abbott Real-Time HIV-1 PCR assaysJean Marie Sire
Laboratoire de Virologie, Hôpital Saint Louis AP HP, INSERM U941, Universite Paris Diderot, Paris, France
J Acquir Immune Defic Syndr 56:239-43. 2011..A new version of the Roche Cobas AmpliPrep/Cobas TaqMan HIV-1 assay (CA/CTM v2.0) has been introduced to overcome the underquantification observed with the first version...
Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trialNathalie de Castro
Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Saint Louis Hospital and University of Paris VII Denis Diderot, Paris, France
Clin Infect Dis 49:1259-67. 2009..We conducted a prospective, randomized, open-label trial to compare the antiviral efficacy and safety of a switch to raltegravir with the efficacy and safety of continuing enfuvirtide...
Sensitivity of five rapid HIV tests on oral fluid or finger-stick whole blood: a real-time comparison in a healthcare settingJuliette Pavie
Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, Universite Paris Diderot, Paris, France
PLoS ONE 5:e11581. 2010..Several HIV rapid tests are now licensed in Europe but their sensitivity on total blood and/or oral fluid in routine healthcare settings is not known...
Darunavir (TMC114): a new HIV-1 protease inhibitorJean Michel Molina
Assistance Publique Hôpitaux de Paris and University of Paris 7, Department of Infectious Diseases, Hopital St Louis, Paris, France
Expert Opin Pharmacother 8:1951-64. 2007..This article reviews the presently available data on darunavir, its pharmacology, pharmacokinetics, drug-drug interactions and clinical trial results, as well as examining darunavir from a health economic perspective...
Severe peripheral neuropathy following HAART initiation in an HIV-infected patient with leprosyJuliette Pavie
Department of Infectious Diseases, Saint Louis Hospital and University of Paris Diderot, Paris, France
J Int Assoc Physicians AIDS Care (Chic) 9:232-5. 2010..Physicians in charge of HIV-infected patients originating from countries endemic for leprosy should be aware of this risk of leprosy-associated IRIS when starting HAART...
Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDSEmmanuelle Boulanger
Department of Clinical Immunology, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 avenue Claude Vellefaux, 75 475 Paris Cedex 10, France
J Clin Oncol 23:4372-80. 2005..The prognosis is poor, with reported median survival time shorter than 6 months. To date, no prognostic factor has been identified in this subset of lymphoma...
A case report of adenovirus-related acute interstitial nephritis in a patient with AIDSElodie Mazoyer
Service de Nephrologie, Hopital Saint Louis, AP HP, Paris, France
Am J Kidney Dis 51:121-6. 2008..This case illustrates another cause of acute kidney disease in very immunosuppressed patients with AIDS, probably underdiagnosed...
Emtricitabine: a novel nucleoside reverse transcriptase inhibitorJean-Michel Molina
, Paris, France
Drugs Today (Barc) 41:241-52. 2005..The now available combination of emtricitabine with tenofovir in the same pill makes it a very attractive backbone combination to use in conjunction with other antiretroviral drugs...
Concentrations of tenofovir and emtricitabine in saliva: implications for preexposure prophylaxis of oral HIV acquisitionVictoire de Lastours
Infectious Diseases Department, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, 1 avenue Claude Vellefaux, 75010 Paris, France
Antimicrob Agents Chemother 55:4905-7. 2011..Mean ratios of saliva/plasma concentration were 3% (±4%) and 86.9% (±124%) for TFV and FTC, respectively. Tenofovir disoproxil fumarate (TDF) should be used in combination with FTC to prevent oral acquisition of HIV...
Severe Actinobacillus ureae meningitis in an immunocompromised patient: report of one case and review of the literatureNathalie de Castro
Infectious Diseases Department, APHP Hôpital Saint Louis, Paris, France
Scand J Infect Dis 39:1076-9. 2007..Risk factors, clinical outcome and treatment of Actinobacillus ureae infections are discussed. Actinobacillus ureae may behave as an opportunistic pathogen causing severe infections in immunocompromised patients...
Restoration of Toxoplasma gondii-specific immune responses in patients with AIDS starting HAARTAndre Furco
Department of Infectious Diseases, Saint Louis Hospital, Assistance Publique Hôpitaux de Paris and University of Paris 7, Paris Diderot, Paris, France
AIDS 22:2087-96. 2008..To study the kinetics and identify factors associated with Toxoplasma-specific immune responses in patients with AIDS starting antiretroviral therapy...
Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trialsChristine Katlama
Universite Pierre et Marie Curie, Paris VI and Hôpital Pitié Salpêtrière, Paris, France
AIDS 23:2289-300. 2009....
Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)Charlotte Charpentier
Laboratoire de Virologie, Assistance Publique Hopitaux de Paris AP HP, Groupe Hospitalier Bichat Claude Bernard, HUPNVS, Universite Paris Diderot, Paris 7, PRES Sorbonne Paris Cité, EA4409, Paris, France
PLoS ONE 8:e53621. 2013..The aim of this virological sub-study of the ANRS 139 TRIO trial was to assess: (i) the evolution of HIV-1 DNA over the first year; and (ii) the association between baseline HIV-1 DNA and virological outcome...
Herpes simplex virus type 2 as a cause of severe meningitis in immunocompromised adultsHerve Mommeja-Marin
Department of Infectious Diseases, Hopital Saint Louis, Assistance Publique Hopitaux de Paris, France
Clin Infect Dis 37:1527-33. 2003..HSV-2 can cause severe meningitis in immunocompromised patients. Early recognition and treatment might improve the outcome of such infections...
Antiretroviral therapy initiation in france: adherence to national guidelines and outcomeVatthanaphone Latthaphasavang
1Department of Infectious Diseases, Saint Louis Hospital, AH HP, and University of Paris Diderot, Paris, France
J Int Assoc Physicians AIDS Care (Chic) 11:40-6. 2012..Objectives and..
Pandemic Influenza A (H1N1) Infection among HIV-Infected Adults in FranceMathieu Tourdjman
1Service des Maladies Infectieuses, Hopital Saint Louis, Paris, France
J Int Assoc Physicians AIDS Care (Chic) 10:229-31. 2011..No severe influenza infection was observed, but a high frequency of secondary bacterial pneumonia is reported among pneumococcal unvaccinated patients...
Antiviral activity and safety of aplaviroc, a CCR5 antagonist, in combination with lopinavir/ritonavir in HIV-infected, therapy-naïve patients: results of the EPIC study (CCR100136)P Yeni
University Hospital Bichat, Paris, France
HIV Med 10:116-24. 2009..This phase IIb study explored the antiviral activity and safety of the investigational CC chemokine receptor 5 (CCR5) antagonist aplaviroc (APL) in antiretroviral-naïve patients harbouring R5- or R5X4-tropic virus...
Efficacy and safety of once-daily regimens in the treatment of HIV infectionJean Michel Molina
Department of Infectious Diseases, Assistance Publique Hopitaux de Paris, Hopital Saint Louis, Universite Paris Diderot, Paris 7, France
Drugs 68:567-78. 2008..Such regimens are likely to improve patient adherence because they are simpler and more convenient than earlier therapeutic regimens...
Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097)Christine Katlama
Département des Maladies Infectieuses et Tropicales INSERM E 0214, Hopital Pitie Salpetriere, 47 83 boulevard de l Hopital, 75651 Paris Cedex 13, France
AIDS 18:217-26. 2004..Both highly potent antiretroviral drug rescue therapy and treatment interruption have been suggested to be effective in patients with multiple treatment failure...
Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidusAlexandre Karras
Service de Nephrologie, Hopital Saint Louis, 75475 Paris Cedex 10, France
Clin Infect Dis 36:1070-3. 2003..Patients receiving tenofovir must be monitored closely for early signs of tubulopathy (glycosuria, acidosis, mild increase in the plasma creatinine level, and proteinuria)...
Inhibitory activity of human immunodeficiency virus aspartyl protease inhibitors against Encephalitozoon intestinalis evaluated by cell culture-quantitative PCR assayJean Menotti
Laboratoire de Parasitologie Mycologie, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75475 Paris Cedex 10, France
Antimicrob Agents Chemother 49:2362-6. 2005..intestinalis growth at concentrations that are achievable in vivo and that the real-time quantitative PCR assay that we used is a valuable tool for the in vitro assessment of the activities of drugs against E. intestinalis...
Aseptic meningitis associated with intravenous administration of dexchlorpheniramineMatthieu Lafaurie
Service des Maladies Infectieuses et Tropicales, Hopital Saint Louis, 1, avenue Claude Vellefaux, 75475 Paris Cedex 10
Ann Med Interne (Paris) 154:179-80. 2003..We describe today a very unusual reaction on intravenous dexchlorpheniramine with this case of aseptic meningitis...
Clinically relevant genotype interpretation of resistance to didanosineAnne Genevieve Marcelin
Department of Virology, Pitie Salpetriere Hospital, 83 Boulevard de l hopital, 75013 Paris, France
Antimicrob Agents Chemother 49:1739-44. 2005..In conclusion, we developed and validated a genotypic score, taking into account mutations negatively and positively impacting the virologic response to ddI...
Major role of hepatitis B genotypes in liver fibrosis during coinfection with HIVKarine Lacombe
INSERM U707, Paris, France
AIDS 20:419-27. 2006....
I223R mutation in influenza A(H1N1)pdm09 neuraminidase confers reduced susceptibility to oseltamivir and zanamivir and enhanced resistance with H275YJerome Legoff
University Paris Diderot, Sorbonne Paris Cité, Paris, France
PLoS ONE 7:e37095. 2012..A new mutation I223R in the neuraminidase (NA) of H1N1pdm09 virus has been reported along with H275Y in immunocompromised patients. The aim of this study was to determine the impact of I223R on oseltamivir and zanamivir susceptibility...
High burden of non-influenza viruses in influenza-like illness in the early weeks of H1N1v epidemic in FranceNathalie Schnepf
Universite Paris Diderot, Sorbonne Paris Cité, Microbiology Department, Saint Louis Hospital, APHP, Paris, France
PLoS ONE 6:e23514. 2011..Clinical observations are of little help to recognise myxovirus infection and implement appropriate prevention measures. The limited use of molecular tools underestimates the role of other common pathogens...
Etiologies and outcome of acute respiratory failure in HIV-infected patientsFrancois Barbier
Medical ICU and Infectious Disease Department, AP HP, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010, Paris, France
Intensive Care Med 35:1678-86. 2009..To assess the etiologies and outcome of acute respiratory failure (ARF) in HIV-infected patients over the first decade of combination antiretroviral therapy (ART) use...
Detection of extensive cross-neutralization between pandemic and seasonal A/H1N1 Influenza Viruses using a pseudotype neutralization assayBeatrice Labrosse
Institut Universitaire d Hematologie, Universite Paris Diderot, Paris, France
PLoS ONE 5:e11036. 2010..In particular, the extent that previous infection or vaccination by seasonal A/H1N1 viruses can elicit protective immunity against pandemic A/H1N1 is unclear...
AIDS-Related Kaposi's Sarcoma Can Occur during Peginterferon-α and Ribavirin Therapy for Chronic Hepatitis C InfectionVictoire de Lastours
1Infectious Diseases Department, Assistance Publique Hopitaux de Paris APHP, Hopital Saint Louis, Paris, France
J Int Assoc Physicians AIDS Care (Chic) 11:9-11. 2012..The absence of ART, despite high CD4 counts, and interferon-induced lymphopenia probably triggered the occurrence of KS in this patient...
Reduction of fluoroquinolone use is associated with a decrease in methicillin-resistant Staphylococcus aureus and fluoroquinolone-resistant Pseudomonas aeruginosa isolation rates: a 10 year studyMatthieu Lafaurie
Infectious Diseases Intervention Unit U2i, Hopital Saint Louis, 1 avenue Claude Vellefaux, 75010, Paris, France
J Antimicrob Chemother 67:1010-5. 2012..aeruginosa rates and antibiotic consumption after implementation of an institution-wide programme to reduce fluoroquinolone use...
Acute kidney disease due to immune reconstitution inflammatory syndrome in an HIV-infected patient with tuberculosisCarine Salliot
Department of Infectious Diseases, Hopital Saint Louis, Paris, France
J Int Assoc Physicians AIDS Care (Chic) 7:178-81. 2008..All published case reports of IRIS revealed by acute renal failure in HIV-infected patients are also reviewed...
Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patientsJulie Bottero
INSERM UMR S707, Paris, France
J Hepatol 50:1074-83. 2009..The aim of this study was to compare the performance of 11 biochemical scores to estimate liver fibrosis in HIV/HBV co-infection...
Interleukin-2 before antiretroviral therapy in patients with HIV infection: a randomized trial (ANRS 119)Jean Michel Molina
Assistance Publique Hopitaux de Paris, Hopital Saint Louis, France
J Infect Dis 200:206-15. 2009..Interleukin (IL)-2 increases CD4 T cell counts when combined with antiretroviral therapy (ART). Whether IL-2 alone can increase CD4 cell counts is unknown...
Disseminated adenovirus infections after allogeneic hematopoietic stem cell transplantation: incidence, risk factors and outcomeMarie Robin
Service d Hematologie, Greffe, Paris, France
Haematologica 92:1254-7. 2007..Risk factors for dAdV in unrelated HSCT recipients were previous Fanconi disease (p=0.03) and GVHD (p=0.02) in children, and cord blood source of stem cells (p=0.029) and GVHD (0.024) in adults...
Treatment of facial lipoatrophy with intradermal injections of polylactic acid in HIV-infected patientsMatthieu Lafaurie
Service des Maladies Infectieuses et Tropicales, , Paris, France
J Acquir Immune Defic Syndr 38:393-8. 2005..CONCLUSIONS: Injections of PLA improved patients' self-perception of facial lipoatrophy, with a good safety profile. The benefit of the procedure, however, decreased with time...
Effects of chemical and physical agents on viability and infectivity of Encephalitozoon intestinalis determined by cell culture and flow cytometryMaud Santillana-Hayat
Parasitology-Mycology Laboratory, Department of Infectious Diseases, Saint-Louis Hospital, AP-HP and EA 3520, University of Paris 7, France
Antimicrob Agents Chemother 46:2049-51. 2002..Surfanios and benzalkonium chloride, disinfectants currently used in the hospital, were remarkably efficient in destroying spore viability and infectivity...
HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral responseJacques Izopet
INSERM U563 IFR30, Universite de Toulouse et Laboratoire de, Virologie, Institut Fédératif de Biologie de Purpan, CHU de Toulouse, France
Antivir Ther 13:537-45. 2008..We aimed here to study drug-associated HIV resistance mutations in peripheral blood mononuclear cells (PBMC) and plasma during intermittent therapy...
Subgroup analyses of maraviroc in previously treated R5 HIV-1 infectionGerd Fatkenheuer
Universitätsklinik Köln, Cologne, Germany
N Engl J Med 359:1442-55. 2008....
Maraviroc for previously treated patients with R5 HIV-1 infectionRoy M Gulick
Weill Cornell Medical College, New York, NY 10065, USA
N Engl J Med 359:1429-41. 2008..CC chemokine receptor 5 antagonists are a new class of antiretroviral agents...
Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adultsPhilippe Lesprit
Henri Mondor Hospital, Creteil, France bINSERM U593, Bordeaux, France
AIDS 21:2425-34. 2007....
HLA-B*5701 screening for hypersensitivity to abacavirSimon Mallal
Royal Perth Hospital and Murdoch University, Perth, Australia
N Engl J Med 358:568-79. 2008..This study was designed to establish the effectiveness of prospective HLA-B*5701 screening to prevent the hypersensitivity reaction to abacavir...
Analysis of undetectable HIV RNA using survival analysis: results must be interpreted carefullyRodolphe Thiebaut
INSERM U593, Institut de Santé Publique d Epidémiologie et de Développement, Bordeaux, France
HIV Clin Trials 4:417-20. 2003..The potential for loss of information might yield differential misclassification biases and therefore unreliable results. Longitudinal models are better suited to analyze the repeated measures of a continuous outcome such as HIV RNA...
[Treatment of the human immunodeficiency virus in adults in 2005]Juliette Pavie
Service des Maladies Infectieuses et Tropicales, Saint Louis, Assistance Publique Hôpitax de Paris, Universite de Paris 7, UFR Lariboisière Saint Louis
Presse Med 34:1S38-44. 2005..In these situations the new antiviral drugs with novel mechanisms of action, such as the entrance inhibitors, are clearly of interest...
Initial therapy with nucleoside reverse transcriptase inhibitor-containing regimens is more effective than with regimens that spare them with no difference in short-term fat distribution: Hippocampe-ANRS 121 TrialClaudine Duvivier
AP HP, Groupe Hospitalier Pitie Salpetriere, Service de Maladies Infectieuses et Tropicales, Paris F 75013, France
J Antimicrob Chemother 62:797-808. 2008..The aim of this study was to evaluate the impact on body fat of nucleoside reverse transcriptase inhibitor (NRTI)-sparing regimens compared with NRTI-containing therapy in HIV-1-infected antiretroviral (ARV)-naive patients...
Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099Valérie Journot
INSERM, U593, Bordeaux, France
Clin Infect Dis 42:1790-9. 2006..Whether the use of EFV is associated with the risk of depression or suicide remains controversial...
Efficacy and safety of emtricitabine vs stavudine in combination therapy in antiretroviral-naive patients: a randomized trialMichael S Saag
University of Alabama Research Clinic, Birmingham, USA
JAMA 292:180-9. 2004..005). CONCLUSION: Once-daily emtricitabine appeared to demonstrate greater virological efficacy, durability of response, and tolerability compared with twice-daily stavudine when used with once-daily didanosine and efavirenz...
A once-daily lopinavir/ritonavir-based regimen provides noninferior antiviral activity compared with a twice-daily regimenMargaret A Johnson
Royal Free Center for HIV Medicine, London, United Kingdom
J Acquir Immune Defic Syndr 43:153-60. 2006..Both regimens were relatively well tolerated, and no LPV or TDF resistance was observed...
Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophyGenevieve Chene
INSERM, U593, F 33076 Bordeaux, France
AIDS Res Hum Retroviruses 23:54-61. 2007..Furthermore, a low mtDNA level at month 12 was associated with the subsequent development of lipodystrophy. This marker may be of value for the early prevention of lipodystrophy in treated HIV-infected patients...
Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patientsGenevieve Chene
INSERM Unité 330, Universite Victor Segalen Bordeaux 2, 33076 Bordeaux Cedex, France
Clin Infect Dis 34:649-57. 2002..4; P=.007). No difference was observed in cholesterol and glucose levels as a function of any pattern of antiretroviral exposure. Exposure to stavudine and didanosine was associated with LD syndrome (predominantly lipoatrophy)...
Structured treatment interruptions in primary HIV-1 infection: the ANRS 100 PRIMSTOP trialBruno Hoen
Department of Infectious Diseases and EA 3186, University Medical Center of Besançon and Université de Franche Comté, Villejuif, France
J Acquir Immune Defic Syndr 40:307-16. 2005....
Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar studyPhilippe Flandre
INSERM U 472, Paul Brousse Hospital, Villejuif, France
Antivir Ther 10:479-87. 2005..To compare non-parametric tests and procedures of selection in building clinically validated genotypic scores...
Intermittent antiretroviral therapy in patients with controlled HIV infectionBruno Marchou
Hopital Purpan, Toulouse, France
AIDS 21:457-66. 2007..To assess the safety of a drug-sparing treatment regimen in patients with high CD4 cell counts and controlled HIV replication under antiretroviral therapy...
Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trialsBonaventura Clotet
Hospital Universitari Germans Trias I Pujol and irsiCaixa Foundation, Ctra de Canyet s n 08916, Barcelona, Catalonia, Spain
Lancet 369:1169-78. 2007..We did a pooled subgroup analysis to update results at week 48 for patients receiving the recommended dose of darunavir-ritonavir compared with those receiving other protease inhibitors (PIs)...
Health-related quality of life with enfuvirtide (ENF; T-20) in combination with an optimized background regimenCalvin J Cohen
Community Research Initiative of New England, Boston, MA 02215, USA
J Acquir Immune Defic Syndr 37:1140-6. 2004..Enfuvirtide in addition to an OB regimen does not adversely affect and may improve HRQoL when self-administered for up to 24 weeks by treatment-experienced, HIV-1-infected individuals...
Topical imiquimod for recurrent acyclovir-resistant HSV infectionValerie Martinez
Am J Med 119:e9-11. 2006
[Acute fever in an immunocompromised patient]Sebastien Gallien
Service de Maladies Infectieuses et Tropicales, Hopital Saint Louis, 75010 Paris
Rev Prat 57:2297-304. 2007
Failure of atovaquone/proguanil to prevent Plasmodium ovale malaria in traveler returning from CameroonSebastien Gallien
Department of Tropical and Infectious Diseases, Saint Louis University Hospital, 75475 Paris Cedex 10, France
Travel Med Infect Dis 6:128-9. 2008..Travelers returned from risk areas with symptoms suggestive of malaria, should not have the diagnosis of P. ovale (or P. vivax) infection discounted, despite a history of compliance with a standard chemoprophylactic regimen...

